Open Nav

Digenomix Corporation

  • Larry Xi, Digenomix Corporation

Seeking Pre-series A investments

  • Date:Thursday, October 18
  • Time:11:30 AM - 11:45 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Digenomix is developing an affordable single-cell DNA sequencing methodology, transforming the currently analog form of NGS into a digital form. This digital revolution will allow us to provide a better diagnostic tool and use the tool to guild cancer treatments. We want to change the current cancer treatment model from pharma-centric to patient-centric.
  • Company
  • Company HQ City:South San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Year Founded:2017
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Digital single-cell DNA sequencing library (TnBC library) construction methodology
  • Development Phase of Primary Product:Discovery
  • Additional Information/Comments:Ancient Chinese statesman Sun Tzi once said, Know yourself and your enemy; That is the way to ensure your success in a war. We can only win the war on cancer, once we have mastered ways to know the cancer. As cancer results from a cascade of mutation events on genome, sequencing the cancer genome with single-cell resolution is the most direct and most comprehensive way to know our enemy.
  • Total Amount Raised to Date, In All Rounds:$500,000
Larry Xi
Digenomix Corporation